Capecitabine (Xeloda)

From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Pyrimidine analog, antimetabolite, inhibitor of thymidylate synthase. Converted in vivo to fluorouracil (5-FU), which is metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP).[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, [ / UpToDate (courtesy of Lexicomp)], or the prescribing information.[1]

Patient drug information


  1. 1.0 1.1 1.2 Capecitabine (Xeloda) package insert
  2. Capecitabine (Xeloda) package insert (locally hosted backup)
  3. Xeloda manufacturer's website
  4. Capecitabine (Xeloda) patient drug information (Chemocare)
  5. Capecitabine (Xeloda) patient drug information (UpToDate)
Personal tools

Stay in touch